Lilly to Acquire Armo BioSciences for $1.6B

Eli Lilly plans to acquire Armo BioSciences for approximately $1.6 billion, the companies said today, in a deal that builds the buyer’s immuno-oncology pipeline with a Phase III pancreatic cancer candidate that is also being developed to treat other solid tumors .AM0010 (pegilodecakin), a long-acting form of recombinant human i nterleukin 10(IL-10) linked to polyethylene glycol (PEG), is now under study in the Phase III Sequoia trial ( NCT02923921 ), designed to compare the treatment&rsquo